Updated on 16 April 2014
Singapore: WuXi PharmaTech, R&D services company with operations in China and United States, has appointed Dr. Steve Yang as Executive Vice President and Chief Operating Officer.
Dr. Yang is a pharmaceutical industry leader recognized for building R&D capabilities, delivering research and early development portfolios of drug candidates, and establishing R&D partnerships in China and other Asian and emerging markets. Before joining WuXi, Dr. Yang was Vice President and Head of Asia and Emerging Markets iMed at AstraZeneca, based in Shanghai.
Previously, Dr. Yang served as Vice President and Head of Asia R&D at Pfizer based in Shanghai, and as Executive Director and head of Pfizer's global R&D strategic management group based in the United States. Before joining Pfizer, Dr. Yang held a number of leadership positions at IntraBiotics Pharmaceuticals, a U.S.-based biotech company. He also worked for Strategic Decisions Group, a strategy consulting firm for Fortune 100 companies. He co-founded the BayHelix Group, a non-profit global professional organization of Chinese life science business leaders, and served as Chairman for two terms.
The Company also announced that Edward Hu will serve as the new Chief Investment Officer in addition to his current role as Chief Financial Officer. Mr. Hu will be responsible for companywide investments, including strategic investments in new businesses, corporate venture capital investments, mergers and acquisitions, and joint ventures. He has served as the Company's Chief Operating Officer since January 2008 and as Chief Financial Officer since February 2009.
"I'm very pleased that Steve has joined WuXi as our Chief Operating Officer, and that Ed will assume additional responsibilities as our Chief Investment Officer," said Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech. "It is heroic efforts of leaders like Ed, with determination to build the best technology, science and capability platform to serve our customers, that have brought WuXi to where we are today. I am thrilled to have the opportunity to work with Ed, Steve, our WuXi leadership team and all of our WuXi colleagues to continue our mission to build the best R&D platform to enable anyone and any company to discover and develop healthcare products to benefit patients."